There is good news today for lung cancer patients. The FDA has announced that it has approved expansion of the immunotherapy drug nivolumab (Opdivo) for certain lung cancer patients.
Julie Brahmer, M.D., oncologist at the Johns Hopkins Kimmel Cancer Center and director of its Thoracic Oncology Program, is one of the leaders of the initial, first-in-human trial of nivolumab and ongoing clinical trials that the FDA reviewed in its decision today to approve nivolumab for advanced squamous cell lung cancer. She says, "This is an exciting development for lung cancer patients today. We're entering a new era of treatment, notably, the first time immunotherapy has shown improved survival outcomes compared to chemotherapy and the first time any type of immunotherapy for lung cancer has been approved. We hope it's the first step to more immune-targeted treatments for lung cancer patients."